Bridgeway Capital Management Inc. bought a new stake in shares of Quanterix Corp (NASDAQ:QTRX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 40,000 shares of the company’s stock, valued at approximately $857,000.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Bellevue Group AG increased its position in shares of Quanterix by 89.3% during the third quarter. Bellevue Group AG now owns 313,230 shares of the company’s stock worth $6,709,000 after purchasing an additional 147,750 shares in the last quarter. FMR LLC increased its position in shares of Quanterix by 0.4% during the third quarter. FMR LLC now owns 1,325,749 shares of the company’s stock worth $28,398,000 after purchasing an additional 5,359 shares in the last quarter. BlackRock Inc. increased its position in shares of Quanterix by 66.2% during the third quarter. BlackRock Inc. now owns 409,721 shares of the company’s stock worth $8,775,000 after purchasing an additional 163,255 shares in the last quarter. PNC Financial Services Group Inc. purchased a new stake in shares of Quanterix during the third quarter worth approximately $428,000. Finally, Bank of New York Mellon Corp increased its position in shares of Quanterix by 33.1% during the third quarter. Bank of New York Mellon Corp now owns 28,855 shares of the company’s stock worth $618,000 after purchasing an additional 7,169 shares in the last quarter. Institutional investors and hedge funds own 49.62% of the company’s stock.
Shares of QTRX opened at $19.50 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.11 and a quick ratio of 3.76. Quanterix Corp has a one year low of $13.00 and a one year high of $24.81. The company has a market cap of $408.22 million and a P/E ratio of -2.35.
Several analysts recently commented on QTRX shares. Zacks Investment Research cut Quanterix from a “hold” rating to a “sell” rating in a research report on Wednesday, August 22nd. Canaccord Genuity reiterated a “buy” rating on shares of Quanterix in a research report on Wednesday, November 7th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $26.67.
In other Quanterix news, Chairman E Kevin Hrusovsky sold 2,995 shares of the company’s stock in a transaction on Tuesday, October 2nd. The stock was sold at an average price of $20.91, for a total value of $62,625.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Ernest Orticerio sold 20,000 shares of the company’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $16.82, for a total value of $336,400.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 77,764 shares of company stock valued at $1,341,815. 31.60% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This story was published by BBNS and is the sole property of of BBNS. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://baseballnewssource.com/2018/12/08/bridgeway-capital-management-inc-buys-shares-of-40000-quanterix-corp-qtrx/3063834.html.
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer.
Read More: How analysts view the yield curve
Want to see what other hedge funds are holding QTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quanterix Corp (NASDAQ:QTRX).
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.